The dedicated treatment indicated a significant decrease in cocaine craving in a sub- group that received Clearmind's MEAI
VANCOUVER, Aug. 24, 2022 -- Clearmind MedicineInc. (CSE: CMND), (OTC Pink: CMNDF), (FSE: CWY0) (“Clearmind” or the "company"), a biotech company focused on discovery and development of novel psychedelic-derived therapeutics to solve major undertreated health problems, today announced additional positive pre-clinical results for treatment for cocaine addiction using MEAI, its novel psychedelic molecule.
"We are very excited by these new results which further strengthen our previous results indicating the potential of our proprietaryMEAI to treat cocaine addiction,” said Dr. Adi Zuloff-Shani, Clearmind's Chief Executive Officer. “As cocaine is extremely addictive and there is currently no dedicated treatment, I believe Clearmind is leading the way in this field. The results, even in this preliminary stage, also show the business impact as we need new and effective therapeutics, and these hold high commercial potential.”
The pre-clinical trial, led by Professor Gal Yadid and his team, from the Gonda Multidisciplinary Brain Research Center located at Bar Ilan University (Ramat Gan, Israel), was designed according to the self-administration paradigm, which is the gold-standard model for examining drug addiction and is based on operant conditioning.
In the present trial, animals were catheterized and trained to self-administer cocaine. After the establishment of the addiction model, rats underwent an extinction phase where no cocaine was administered and MEAI was given to the test group. Finally, a relapse phase was carried out where the addicted rats were reminded of the drug with a single administration and then the animals were returned to the self-administration habitat, without receiving the drug. The assumption is that the more an animal yearns to receive the drug, the more it will press on the active pedal.
The results identified a sub-group within the study, in a non-biased manner and with high integrity, which dramatically responded to the treatment, significantly decreasing the craving for cocaine, as compared to non-treated control group.
This sub-group, representing 60% of animals, showed very high response, within the group and across the board. This pattern of results aligns with a previous Clearmind study which tested the conditioned place-preference paradigm, where similar sub-population group was identified in the context of cocaine preference. This research demonstrates again MEAI’s unique ability to treat cocaine addiction and its potential to become the first dedicated cocaine addiction treatment.
About Clearmind Medicine Inc.
Clearmind is a new biotech company focused on the discovery and development of safe and novel psychedelic-derived therapeutics to treat alcohol use disorder and other pressing health challenges.
The Israeli- Canadian company holds several patents for the non-hallucinogenic compound MEAI (5-methoxy-2-aminoindane, a novel psychoactive substance). The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
Clearmind has established a research collaboration with the HebrewUniversity of Jerusalem and Bar Ilan University. The partnerships aim to expand its R&D capabilities and discover new candidate treatments for other mental health issues.
Shares of Clearmind are listed for trading on the CanadianSecurities Exchange under the symbol "CMND", the Frankfurt StockExchange under the symbol “CWY0” and on the OTC pink under the symbol"CMNDF".
For further information, please contact:
Telephone: (604) 260-1566
This news release may contain forward-looking statements and information based on current expectations. These statements should not be read as guarantees of future performance or results. Such statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by such statements. Such statements include submission of the relevant documentation within the required timeframe to the satisfaction of the relevant regulators and raising sufficient financing to complete the Company's business strategy. There is no certainty that any of these events will occur. Although such statements are based on management's reasonable assumptions, there can be no assurance that such assumptions will prove to be correct. We assume no responsibility to update or revise them to reflect new events or circumstances.None of the Company’s product have received FDA approval and are not commercially available.
Investing into early-stage companies inherently carries a high degree of risk, and investment into securities of the Company shall be considered highly speculative.
Neither the Canadian Securities Exchange (the “CSE”) nor itsRegulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.